Open access peer-reviewed chapter

Role of Dietary Carotenoids in Different Etiologies of Chronic Liver Diseases

By Uzma Latief and Riaz Ahmad

Submitted: March 9th 2018Reviewed: August 1st 2018Published: November 5th 2018

DOI: 10.5772/intechopen.80650

Downloaded: 338

Abstract

Carotenoids are tetraterpenoid organic pigments synthesized by a variety of plants and microorganisms. Dietary carotenoids, taken by animals through food, play an essential role in cell differentiation, morphogenesis, vision, prevention of cancer, atherosclerosis, and age-related macular degeneration in humans due to their potential to suppress oxidative stress. As reactive oxygen species and oxidative damage to biomolecules have been found to be involved in the causation and progression of chronic liver diseases (CLDs), including hepatocellular carcinoma (HCC), which is one of the major causes of morbidity and mortality worldwide. Therefore, dietary antioxidants, which inactivate reactive oxygen species and obstruct oxidative damage, are considered as vital prophylactic strategic molecules. Data from various epidemiological studies and clinical trials strongly validate the observation that adequate carotenoid supplementation may significantly reduce the risk of several liver disorders. This chapter, thus, provides a comprehensive account of dietary carotenoids and includes the recent information with respect to their role in prevention of liver diseases.

Keywords

  • β-carotene
  • lycopene
  • lutein
  • β-cryptoxanthin
  • oxidative stress
  • chronic liver diseases

1. Introduction

There are unambiguous evidences that regular consumption of vegetables and fruits decreases the prevalence of chronic liver disease (CLD) [1, 2]. One of the main reasons of the health organizations to increase the consumption of vegetables and fruits is that these are good sources of carotenoids and other biologically active phytochemicals. Carotenoids are naturally occurring tetraterpenoids and represented by approximately 700 different structural variants, but only 50 have been reported to play an important role in human diet [3]. They are synthesized by plants, fungi, algae, and bacteria [4]. They are classified into two groups, carotenes containing only carbon and hydrogen atoms and xanthophylls containing at least one oxygen atom [5]. These carotenoids are further paired into two classes, provitamin A carotenoids (β-carotene and β-cryptoxanthin) and non-provitamin A carotenoids (lycopene and lutein) [6]. In animals and human beings, carotenoids particularly β-carotene, lycopene, lutein, and β-cryptoxanthin play an important role in protection against photooxidative damage by acting as singlet molecular oxygen and peroxy radical scavenger [7, 8]. There are increasing evidences that an alteration of the cellular redox state involving production of reactive oxygen species (ROS) plays a central role in different steps that initiate and regulate the progression of various liver diseases irrespective of the cause. Liver damage caused by reactive oxygen species is induced by alcohol, alteration of lipid, viruses, carbohydrate metabolism, and xenobiotics [9]. In this context, provitamin A activity of these carotenoids [10, 11] has received considerable interest by researchers and health professionals to prevent chronic liver diseases.

Chronic liver diseases (CLDs) are the major concern throughout the world because of the increasing death rate due to them. CLDs such as alcoholic liver disease (ALD), nonalcoholic fatty liver disease (NAFLD), and viral hepatitis (B and C) progress to fibrosis, cirrhosis, and ultimately hepatocellular carcinoma (HCC) [12, 13]. HCC is the fifth most common type of cancer and third most common cause of cancer mortality throughout the world [14]. Globally, liver cancer is responsible for causing more than 700,000 deaths annually [15]. Oxidative stress resulting from various sources is a major mechanism for hepatic fibrosis and cirrhosis [16]. The major source of ROS in hepatocytes is the mitochondria. Hepatocytes contain many mitochondria and thus have high production of ROS. An imbalance between the production of ROS and antioxidant defense generates various pathophysiological alterations in the hepatic cells, such as activation of hepatic stellate cells (HSCs), initiation of collagen formation, and beginning of proliferative processes [17, 18, 19, 20, 21]. HSCs are responsible for storage of more than 90% of the body’s vitamin A content as retinyl esters in normal liver. Chronic liver injuries may cause these cells to undergo activation and lose their capacity to store vitamin A while acquiring pro-inflammatory and proliferative properties, responsible for fibrogenesis [22]. Fibrosis if not treated may lead to end stage of liver damage, that is, liver cancer (Figure 1) [15, 23, 24].

Figure 1.

Functions of various dietary carotenoids against chronic liver diseases.

In this context, dietary carotenoids being an important part of antioxidant defense system and precursor of vitamin A play an important role in the prevention of chronic liver diseases. Nowadays, due emphasis is given on the search of alternative therapeutics or medicines as these have least side effects and are cost effective. In this context, this chapter focuses on the use of dietary carotenoids in chronic liver disease prevention which have been documented extensively in the recent literature.

2. β-Carotene and chronic liver diseases

β-Carotene is the major carotenoid present in human diet. It is mainly present in plant sources of human diet such as carrots, pumpkin, spinach, sweet potato, cantaloupe, papaya, and mangoes [25]. It is a potent quencher of singlet oxygen, scavenges peroxy radicals, reduces levels of reactive oxygen species, and augments the investigated antioxidant enzyme activities [26, 27]. It is also a precursor of vitamin A and is reportedly converted to vitamin A by the action of β-carotene 15,15′-monooxygenase [10].

Various studies have demonstrated the hepatoprotective potential of β-carotene carried out in animal models, cell lines, and human beings. Patel and Sail reported that β-carotene protects the physiological antioxidants against aflatoxin-B1-induced carcinogenesis in albino rats [28]. β-Carotene supplementation increases the levels of vitamin C, glutathione, and glutathione-related enzymes which function as free radical scavenger and, thus, reduces the toxicity of aflatoxin-B1 in rats. In another study, it was found that various antioxidants including β-carotene modulate the hepatotoxicity induced by aflatoxin-B1 [29]. Both HBV and HCV have been found to elevate inflammatory and oxidative conditions in hepatocytes. Moreover, in chronic liver diseases, hepatic stellate cells, which store almost 70–90% of vitamin A, become activated, lose their retinoid content, and produce extracellular matrix, which is responsible for liver fibrosis [30]. Hepatic fibrosis can lead to cirrhosis and in some cases hepatocellular carcinoma (HCC). Through its provitamin A activity and roles in inhibiting reactive oxygen species, β-carotene has been shown to ameliorate the development and progression of HBV- and HCV-induced HCC. In a human study, it was found that the oxidative stress increased in patients with chronic hepatitis C (CHC). Various antioxidants such as retinol, α- and γ-tocopherol, β-cryptoxanthin, lycopene, and α- and β-carotene were decreased in serum of CHC patients, and levels in liver tissue seem to reflect serum levels [31]. In Chinese patients, it was observed in Chinese patients that the serum levels of retinoids are low in HBV-induced HCC [32, 33]. In another study, it was shown that a high percentage of patients have vitamin A deficiency in serum in chronic hepatitis C [34, 35]. This condition reflects no response to antiviral therapy, indicating that serum levels of vitamin A could regulate the responsiveness to interferon-based antiviral therapy [35].

The generation of very high levels of oxidative stress during the metabolism of alcohol may exceed the antioxidant defense ability of the body and cause the development of liver dysfunction. It has been reported that β-carotene exerts protective effect on chronic ethanol-fed rats [36]. It was shown that ethanol treatment causes increase in oxidative stress which could stimulate apoptosis in the liver, thus leading to liver injury. However, the lower dose of β-carotene supplementation (0.52 mg/kg BW/day), which acted as an antioxidant, decreased the ROS level by downregulating lipid peroxidation and CYP2E1 expression. Moreover, it prevented ethanol-induced liver damage by impeding hepatic apoptosis via inhibiting caspase-9 and caspase-3 expressions and increasing Bcl-xL expression in the liver. In addition, the higher dose of β-carotene supplementation (6.2 mg/kg BW/day) possibly halted ethanol-induced liver damage through inhibiting TNF-α secretion and lipid peroxidation in ethanol-fed rats. Literature revealed that β-carotene supplementation can prevent liver damage in rats with chronic alcohol consumption [37, 38]. β-carotene supplement is known to attenuate ethanol-induced liver damage, decreased oxidative stress and increased GSH concentrations in erythrocytes and the liver. β-Carotene may act as an antioxidant, scavenging lipophilic radicals produced by ethanol within the membranes [39]. In a human study, it was found that in alcoholic patients with liver damage, the plasma β-carotene level was found to be lowered than in control subjects [40]. ALD is also associated with depleted levels of hepatic vitamin A [41]. As β-carotene is the precursor of vitamin A, thus, the supplementation of this carotenoid tends to regain the hepatic vitamin A content, thus facilitating attenuation of the disease.

In a study, it was found that dietary intake of apricot reduced the risks of hepatic steatosis and damage induced by CCl4 in Wistar rats [42]. Apricot is believed to have high content of carotenoids, especially β-carotene. Markers of oxidative stress such as malondialdehyde, total GSH levels, catalase, SOD, and GSH peroxidase activities were significantly altered by CCl4 indicating increased oxidative stress. Hepatic damage and steatosis imposed by high concentration of ROS were ameliorated by β-carotene-rich apricot intake. Consumption of tomato juice which contains lycopene and β-carotene as the major components reduces plasmatic triglycerides, steatosis, and very low-density lipoproteins. Also, it elevates lipid metabolism by inducing the overexpression of genes involved in more efficient fatty acid oxidation in rats [43]. It is also shown that Campari tomato, which contains more β-carotene and lycopene than regular tomato, ameliorated diet-induced obesity, dyslipidemia, and hepatosteatosis via downregulation of gene expression related to lipogenesis in the zebra fish model. It decreased sterol regulatory element-binding transcription factor 1 (SREBF1) mRNA by increasing the forkhead box O1 (foxo1) gene expression. This may be due to high percentage of β-carotene in this strain of tomato which is responsible for downregulating the expression of SREBF1 [44]. In Chinese population greater levels of carotenoids such as β-carotene in serum have been correlated with low prevalence of NAFLD [45]. These carotenoids mediate the protective effects against NAFLD through antioxidant mechanism, enhancing gap junction communication, reducing inflammation, and modulation of gene expression. In another human study, it was found that NAFLD has reverse relationship with vitamin A nutritional status in individuals with class III obesity. Retinol and β-carotene serum levels were evaluated as biochemical indicators. The researchers observed low serum retinol and β-carotene serum levels in the patients with NAFLD [46].

In one study, β-carotene and vanadium inhibit the diethylnitrosamine (DEN)-induced hepatic carcinogenesis in rats [47]. It was observed that treatment of β-carotene and vanadium reduced the number and size of the hyperplastic nodules significantly, while the combination treatment proved as an additive effect, decreasing number and size of the hyperplastic nodules from 89 to 22%. Further, it significantly reduced the level of cytosolic glutathione and glutathione-S-transferase (GST) activity and stabilized the aerobic metabolism and hepatic architecture of the cells. In another study involving cell lines, it was found that acyclic retinoid (synthetic analog of retinoids) retards overexpression of Ras/Erk signaling system, thereby declining the progression of HCC [48]. In a human study, it was found that greater intake of retinol, total vitamin A, and carotenes decreases the risk of primary liver cancer at an intake of 1000 μg retinol equivalent (RE)/day or greater from food sources [49]. In another human study in the presence of hepatitis B virus, levels of dietary and serum vitamin A and β-carotene were significantly lower in HCC patients than in the control subjects [32].

3. Lycopene and chronic liver diseases

Lycopene, like other carotenoids, is a natural pigment mainly present in tomato and products of tomato. It is also present in watermelon, apricot, pink guava, pink grapefruit, and papaya [50]. It does not show provitamin A activity since it lacks the β-ionone ring structure which is characteristic in other carotenes that are precursors of vitamin A [50, 51]. Various studies showed that lycopene possesses antioxidant, anticancer, anti-cardiovascular disease, and detoxification abilities in many epidemiological and animal experiments with few side effects [52, 53, 54].

As a dietary phytochemicals, lycopene has been demonstrated to mitigate AFB1-induced adverse effects in vitro and in vivo. The carcinogenicity of aflatoxin B1 (AFB1) in HepG2 cells was prevented by lycopene through decreasing DNA damage and AFB1-N7-guanine (AFB1-N7-Gua) adduct formation [55]. In another study, it was found that lycopene, because of its high antioxidant activity and free radical scavenging capacity, has been shown to be effective against oxidative stress due to aflatoxin. Lycopene blocks phase 1 metabolic enzymes of AFB such as 3A4, 2A6, and 1A2 [56]. In another study, lycopene relieves AFB1-induced liver injury through enhancing hepatic antioxidation and detoxification potential with Nrf2 activation [57]. Lycopene, a nutritional antioxidant, has also been shown for its hepatoprotective potential in D-galactosamine/lipopolysaccharide (D-GalN/LPS)-induced hepatitis in rats [58, 59]. It is able to affect the lipoprotein metabolism by restoring the altered levels of lipid-metabolizing enzymes and stabilizing the arrangement of lipoprotein levels during experimentally induced hepatitis. Another study demonstrated that the regular use of our carotenoid-based functional food minimizes the severity of ribavirin-induced anemia in patients with CHC and improves tolerance to the full dose of antiviral therapy [60]. It was found that a mixture of various carotenoids particularly lycopene seems to be promising for the prevention of liver cancer in hepatitis virus-infected patients with cirrhosis [61, 62].

It is found that tomato powder which is rich in lycopene acts as a novel candidate for prevention against alcohol-related hepatic injury in rodents [63]. It provides protection against alcohol-induced liver injury by suppressing CYP450 2E1 induction. It has been reported that lycopene prevents nonalcoholic steatohepatitis induced by high-fat diet [64, 65, 66]. It can reduce high-fat diet-induced steatohepatitis by reducing oxidative stress to the cells. It has been also shown that incorporation of lycopene in balanced diet prevents NAFLD [67, 68]. Lycopene may be a useful functional compound for treating NAFLD by regulating hepatic lipid metabolism [69]. Lycopene inhibits the downregulation of miR-21, which led to the downregulation of fatty acid-binding protein 7 (FABP7) at both the transcriptional and translational levels, thus inhibiting hepatic steatosis induced by high-fat diet.

Lycopene also showed beneficial effects against hepatocellular carcinoma. It provides protection against HCC by modulation of cellular proliferation, glycolysis, and ultrastructure of hepatic cells [70]. Lycopene supplementation also prevents high-fat diet-induced HCC incidence in mice. It suppressed oncogenic signals, including methionine mRNA, β-catenin protein, and mammalian target of rapamycin (mTOR) complex 1 activation. These results provide novel experimental evidence that dietary lycopene and its metabolites can be used to prevent liver cancer and reduce cancer risk in patients with NAFLD [71].

4. Lutein and chronic liver diseases

Lutein is a non-provitamin A carotenoid that belongs to the oxycarotenoid family. It is present in dark green leafy vegetables, such as kale and spinach and eggs [72, 73]. It is commercially prepared from the marigold flower (Tagetes erecta L.) in which it occurs at 1.5–1.8%. It directly quenches free radicals, especially singlet oxygen species [74].

Lutein possesses an antiviral activity against hepatitis B. It exerts its antivirus effects through inhibition of hepatitis B virus transcription [75]. Because of its strong antioxidant potential, lutein has been shown to provide protection against ethanol-induced hepatic damage [76]. It increases levels of antioxidant enzymes, like superoxide dismutase, catalase, glutathione peroxidase, and glutathione, and decreases levels of hydroxyproline. Another study demonstrated that lutein attenuates alcohol-induced liver damage in rats by regulating inflammation and oxidative stress [77]. Its supplementation downregulated inflammatory proteins and cytokines with collateral upregulation of Nrf2 levels and antioxidant enzymatic activities. Lutein decreases inflammation and oxidative stress in the liver and eyes of guinea pigs fed with hypercholesterolemic diet [78]. This carotenoid could prevent degenerative conditions of the liver by decreasing the free cholesterol pool and attenuating lipid peroxidation and pro-inflammatory cytokine production. Further, attenuated inflammatory state in the liver could be explained by decreased NF-κB DNA-binding activity. Another study demonstrated that lutein possesses ameliorative effect against NAFLD [79]. It suggests that lutein supplementation could protect against hepatic lipid accumulation and insulin resistance induced by high-fat diet, possibly via the activation of the expression of sirtuin 1 (SIRT1) and, subsequently, peroxisome proliferator activated receptor (PPAR)-α and other key factors in insulin signaling [80]. Sirtuin 1 is reported to have therapeutic potential in NAFLD and play a key role in insulin sensitivity. SIRT1 regulates the expression of PPAR-α, a key factor in the regulation of lipid metabolism [81, 82]. Lutein has also been found to have anticarcinogenetic effects against NDEA-induced HCC in rats [83]. Inhibition of carcinogenesis by this carotenoid could be because of the combined effect of its antioxidant activity along with the inhibition of cytochrome P450 enzymes, inducing detoxifying enzymes such as glutathione-S-transferase and UDP glucuronyl transferase.

5. β-Cryptoxanthin and chronic liver diseases

β-Cryptoxanthin is an oxygenated carotenoid usually present in squash, pepper, papaya, sweet pickles, carrots, and orange juice [84]. It is a xanthophyll carotenoid specifically found in the Satsuma mandarin (Citrus unshiu Marc.). Similar to other carotenoids, β-cryptoxanthin has an antioxidant activity [85, 86]. β-Cryptoxanthin is readily absorbed and relatively abundant in human plasma, together with β-carotene, lycopene, lutein, and zeaxanthin [87].

It has been shown that β-cryptoxanthin ameliorates diet-induced nonalcoholic steatohepatitis by repressing inflammatory gene expression in mice [88]. β-Cryptoxanthin suppressed the expression of lipopolysaccharide (LPS)-inducible and TNFα-inducible genes in NASH. Elevated levels of the oxidative stress marker thiobarbituric acid-reactive substances (TBARS) were lowered by β-cryptoxanthin in NASH. Thus, it represses inflammation and the resulting fibrosis probably by primarily repressing the increase and activation of macrophages and other immune cells. Reducing reactive oxygen species is likely to be a major mechanism of inflammation and injury suppression in the livers of mice with NASH. Another study revealed that β-cryptoxanthin reversed steatosis, inflammation, and fibrosis progression in preexisting NASH in mice [89]. Thus, β-cryptoxanthin prevents and reverses insulin resistance and steatohepatitis through decreasing activation of macrophages or Kupffer cells in a lipotoxic model of NASH. It was found that plasma levels of carotenoids such as β-carotene, lycopene, lutein, and β-cryptoxanthin were decreased in patients with NASH [90]. This study suggests that antioxidant supplementation may be a rational option for the treatment of NASH. In patients of NAFLD, it was found that β-cryptoxanthin treatment inhibits its progression [91]. β-Cryptoxanthin supplementation is very effective in raising antioxidant and anti-inflammation activities in patients of NAFLD (Table 1).

S. No.Carotenoid investigatedObject of studyResultsReferences
1β-CaroteneRat liverLiver antioxidant enzymes such as glutathione peroxidase, glutathione-S-transferase, catalase, and vitamin C were elevated[28]
2β-Carotene, vitamin E, selenium, silymarin, and coenzyme Q10Rat liverβ-Carotene intake restored the levels of hepatic glutathione, RNA, and serum protein thiols relative to control animals[29]
3β-CaroteneRat liverOxidative stress is decreased by CYP2E1 expression and lipid peroxidation. β-Carotene also inhibited hepatic apoptosis via inhibiting caspase-3 and caspase-9 and increasing Bcl-xL expression in the liver[36]
4Retinol, α- and γ-tocopherol, lutein, β-cryptoxanthin, lycopene, and α- and β-caroteneHuman liver and serumIncreased oxidative stress is present in patients with chronic hepatitis C. Antioxidants were severely depleted in serum and liver tissue[31]
5β-CaroteneRat liverβ-Carotene prevented ethanol-induced lipid peroxidation in hepatic tissues[38]
6β-CaroteneRat liverMalondialdehyde, total glutathione levels and catalase, superoxide dismutase, and glutathione peroxidase activities were restored[42]
7α- and β-Carotene, lutein, and zeaxanthinHuman serumSerum carotenoid levels were inversely associated with the risk of NAFLD[45]
8Dietary carotenes and vitamin AHuman liverDietary consumption of retinol, carotenes, and total vitamin A decreases the risk of primary liver cancer risk[49]
9β-Carotene, β-apo-8′-carotenal, canthaxanthin, astaxanthin, and lycopeneRat liverCarotenoids exert protective effect against aflatoxin B1-induced liver preneoplastic foci and DNA damage[55]
10LycopeneRat liverEnhanced hepatic antioxidant and detoxification potential[57]
11LycopeneRat liverLiver function test enzymes, cholesterol, triglycerides, free fatty acids, and phospholipids in serum and liver were restored[58]
12LycopeneRat liverIt restored the increase in very-low-density lipoproteins, decrease in high-density lipoproteins, and lipid-metabolizing enzymes[59]
13LycopeneRat and mouse liverHepatic CYP2E1 protein levels, peroxisome proliferator-activated receptor-α, inflammatory gene expression, and reticulum stress markers were restored[63]
14LycopeneRat liverSupplementation with lycopene lowered serum malondialdehyde and tumor necrosis factor (TNF-α) levels and elevated liver GSH level[64]
15LycopeneRat liverLycopene treatment reverted changes in liver weight, serum low-density lipoproteins, total hepatic cholesterol, and activity of hepatic SOD, catalase, and glutathione peroxidase[68]
16LycopeneRat liverLycopene supplementation downregulated TNF-α and CYP2E1 expression and decreased infiltration of liver fats[67]
17LycopeneRat liverLycopene provides protection against NAFLD by alleviating amino acid depletion, recovery of the redox balance in liver, and incrementing L-carnitine levels[65]
18LycopeneMouse liverIt decreases the expression of cell proliferation-associated genes (PCNA, cyclin D1, and p21) and glycolytic enzymes[70]
19LycopeneMouse liverLycopene and its metabolites reduce cancer in NAFLD[71]
20LuteinHuman hepatoblastoma cellsLutein inhibited the activity of HBV full-length promoter[75]
21LuteinRat liverSOD, catalase, glutathione peroxidase, glutathione, and hepatic hydroxyproline content were restored by lutein[76]
22LuteinRat liverInflammatory proteins such as NF-κB, COX-2, and iNOS were downregulated along with the upregulation of Nrf2 levels and activities of antioxidant enzymes[77]
23LuteinRat liverLutein administration decreased serum and hepatic cholesterol and triglyceride. It also increased the expression of key factors involved in hepatic insulin signaling[79]
24LuteinRat liverLutein treatment inhibits cytochrome P450 enzymes and increases detoxifying enzymes such as glutathione-S-transferase and UDP glucuronyl transferase[83]
25β-CryptoxanthinMouse liverβ-Cryptoxanthin reduced the levels of TBARS and suppressed the expression of lipopolysaccharide and TNF-α inducible gene. It further suppressed the activation of macrophages, T helper, and cytotoxic cells[88]
26β-CryptoxanthinMouse liverβ-Cryptoxanthin reduced total hepatic macrophage content[89]
27β-CryptoxanthinHuman liverβ-Cryptoxanthin induced antioxidant and anti-inflammatory activities in NAFLD patients[91]
28FucoxanthinHuman liverIt reduced liver and body fat content and improved liver function tests[93]

Table 1.

Effects of carotenoids on chronic liver diseases in cell line, human, and animal models.

6. Other carotenoids and chronic liver diseases

Other carotenoids such as α-carotene, fucoxanthin, and zeaxanthin also show promising effects against chronic liver injury. It has been found that α-carotene has an inhibitory effect on spontaneous liver carcinogenesis in male mice [92]. α-Carotene significantly decreases the mean number of hepatomas per mouse. In another study, it was found that fucoxanthin promoted weight loss, reduced body and liver fat content, and improved liver function tests in obese nondiabetic women [93]. Zeaxanthin also shows protective effects against nonalcoholic steatohepatitis [94]. It significantly prevented NASH progression by decreasing oxidative stress and liver fibrosis. It has been found also that zeaxanthin showed therapeutic effects against alcoholic liver diseases [95]. Zeaxanthin show protective effects through the lower expression level of cytochrome P450 2E1 (CYP2E1), diminished activity of nuclear factor kappa B (NF-κB) through the restoration of its inhibitor kappa B alpha (IκBα), and the modulation of MAPK pathways including p38 MAPK, JNK, and ERK.

7. Conclusions and future directions

Various epidemiological studies investigate the effects of dietary carotenoids on various markers of oxidative stress and inflammation indicating their preventive role in chronic liver disease prevention. Oxidative stress is clearly associated with the etiology of chronic liver diseases. Thus, the use of carotenoid-rich fruits and vegetables should be the part of diet (Tables 2 and 3). Although several pathways related to inhibition of oxidative stress by carotenoids have been uncovered, many aspects remain poorly understood and warrant further research. As many carotenoids have been found to have provitamin A activity, the mechanism related to their regaining of vitamin A content by hepatic stellate cells and restoring their normal functions should be properly understood (Figure 2).

Dietary sourcesβ-CaroteneLycopeneLuteinβ-Cryptoxanthin
Apricot (dried)17.6$0.9$
Carrot (raw)7.9$
Spinach (raw)4.1$11.9$
Kale4.7$15.8$
Tomato juice8.6$
Avocado (raw)0.053#0.036#
Grape fruit, pink (raw)3.4$
Guava (raw)5.4$
Corn, sweet (cooked)1.8$
Papaya (raw)0.276#0.761#
Orange (raw)0.051#0.187#0.122#
Sweet potato (raw)8.8$
Lettuce (raw)1.27#2.6#
Watermelon (raw)0.295#4.8#0.017#0.105#
Cabbage (raw)0.065#0.310#
Broccoli (raw)2.4#0.78#
Brussels sprouts (raw)0.45#1.5#
Peas, green (raw)0.48#
Tangerine (raw)0.071#0.243#0.485#
Pepper, sweet red (raw)2.379#2.205#

Table 2.

Dietary sources of major carotenoids (mg/100 g).

Derived from Arscott [96].


Derived from Johnson [97].


S. no.CarotenoidRecommended daily dose (mg)References
1β-Carotene7[98]
2Lycopene35[99]
3Lutein1–4[100]
4β-Cryptoxanthin3[91]

Table 3.

Ingestion levels of dietary carotenoids to prevent liver diseases.

Figure 2.

Hypothesis of progression of chronic liver diseases and their prevention by dietary carotenoids.

There is further need of long-term controlled trials in normal and diseased groups to study the dose response of each dietary carotenoid. Future research areas may include their bioavailability, metabolism, safety, and mechanism of action. Studies on the type of carotenoid and its metabolites which may act as a suitable regulator to alter pathways related to oxidative stress, inflammation, and carcinogenicity shall also be among the priority areas. However, studying the molecular targets of these dietary carotenoids cannot be ignored and be given full consideration.

Acknowledgments

The authors sincerely thank the Chairman of the Department of Zoology for necessary facilities. UL acknowledges the financial assistance from UGC-Maulana Azad National Fellowship.

Conflict of interest

The authors declare no potential conflict of interest and are responsible for the writing and content of the chapter.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Uzma Latief and Riaz Ahmad (November 5th 2018). Role of Dietary Carotenoids in Different Etiologies of Chronic Liver Diseases, Descriptive Food Science, Antonio Valero Díaz and Rosa María García-Gimeno, IntechOpen, DOI: 10.5772/intechopen.80650. Available from:

chapter statistics

338total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Quality of Reduced-Fat Dairy Coffee Creamer: Affected by Different Fat Replacer and Drying Methods

By Simin Hedayatnia and Hamed Mirhosseini

Related Book

First chapter

Food Safety and Agro-Environment in China: Perceptions and Behaviors of Farmers and Consumers

By Teruaki Nanseki and Min Song

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us